ClinicalTrials.gg
TerminatedNCT03922711Updated Jul 1, 2022Results posted

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

A Phase 2 interventional study of Pridopidine and Placebo in Parkinson Disease, sponsored by Prilenia. Terminated at 33 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Prilenia · Phase 2, Interventional, and Treatment

Why this study was terminated
COVID-19

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
804th of 1,256
23 · median 36
Started
2019
with 104 others
Phase 2
234 of 1,649
25 open now
Registered
962nd of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 804th largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2019, is one of 234 in phase 2, and was the 962nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs. placebo for the treatment of Levodopa Induced Dyskinesia (LID) in patients with Parkinson Disease.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Levodopa
  • Dyskinesia
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provides signed form.
  • Has clinical diagnosis of Parkinson's Disease (PD).
  • Has Levodopa-induced dyskinesia (LID).
  • Patient and/or study partner must demonstrate ability to keep accurate home diary of PD symptoms.
  • Has stable anti-PD treatments for at least 28 days prior to start of study treatment and kept constant throughout study.
  • All routine and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must be at stable dosage for at least 28 days prior to start of study treatment and maintained throughout study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of atypical Parkinsonism.
  • Treatment with dopamine blocking drugs.
  • History of surgical intervention related to PD, such as deep brain stimulation.
  • History of severe depression, psychosis or hallucinations within 6 months prior to screening; active suicidal ideation; or suicidal attempt within 5 years prior to screening.
  • History of certain cancers within 5 years prior to screening.
  • Significant cardiac event within 12 weeks prior to Baseline or history of certain cardiac arrhythmias.
  • History of epilepsy or seizures within 5 years prior to screening.
  • Females who are pregnant or breastfeeding.
  • Sexually active female patients who are not surgically sterile or at least 2 years prior to screening, and who do not agree to utilize a highly effective hormonal method of in combination with a barrier method, from screening until at least 4 weeks after completion of study treatment.
  • Male patients not using highly effective contraception or not agreeing to continue highly effective contraception until at least 90 days after the completion of study treatment.
  • Treatment with any product within 30 days of screening or plans to participate in another clinical study assessing any investigational product during the study.

Other protocol-defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Pridopidine Dose 1

    Dose 1 (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period

    Drug: Pridopidine · Drug: Placebo

  • Experimental
    Pridopidine Dose 2

    Dose 2 for (oral capsule) for 12 weeks following 2 or 4 week dosage regimen titration period

    Drug: Pridopidine

  • Placebo comparator
    Placebo

    Matching placebo (oral capsule) for 16 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Levodopa-induced Dyskinesia as Measured by UDysRS Score

    Mean change from baseline (BL) in the sum of Parts 1, 3 and 4 of the Unified Dyskinesia Rating Scale (UdysRS), in the ON state. The UDysRS comprises 2 primary sections i.e. Historical \[Part 1 (ON-Dyskinesia) and Part 2 (OFF-Dystonia)\] and Objective \[Part 3 (Impairment) and Part 4 (Disability)\] assessment. ON-Dyskinesia are choreic and dystonic movements that occur when the Parkinson's disease (PD) medicine is working. Lower UDysRS values mean better patient outcome i.e. less dyskinesia. The UDysRS score for this study is calculated as sum of the parts, with scores of 0-44 for Part 1, 0-28 for Part 3 and 0-16 for Part 4.

    Time frame: Baseline; Visit 7 (at Week 16) planned. Since the study was terminated early due to the COVID-19 pandemic, analysis of the primary endpoint was done at Visit 5 (Week 8/10) in those patients who were on study drug at this visit.

07

Results

Posted Jul 1, 2022
Limitations and caveats
The study was terminated early due to the COVID-19 pandemic.

Participant flow

Participant flow — Overall Study
MilestonePridopidine 100 mg BIDPridopidine 150 mg BIDPlacebo
Started788
Treatment group based on maximal possible highest dose received (used for analysis)1238
Completed334
Not completed454
Withdrew: Adverse event322
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject031
Withdrew: Not further specified001

Outcome measures

PrimaryChange From Baseline in Levodopa-induced Dyskinesia as Measured by UDysRS Score

Mean change from baseline (BL) in the sum of Parts 1, 3 and 4 of the Unified Dyskinesia Rating Scale (UdysRS), in the ON state. The UDysRS comprises 2 primary sections i.e. Historical \[Part 1 (ON-Dyskinesia) and Part 2 (OFF-Dystonia)\] and Objective \[Part 3 (Impairment) and Part 4 (Disability)\] assessment. ON-Dyskinesia are choreic and dystonic movements that occur when the Parkinson's disease (PD) medicine is working. Lower UDysRS values mean better patient outcome i.e. less dyskinesia. The UDysRS score for this study is calculated as sum of the parts, with scores of 0-44 for Part 1, 0-28 for Part 3 and 0-16 for Part 4.

Time frame:
Baseline; Visit 7 (at Week 16) planned. Since the study was terminated early due to the COVID-19 pandemic, analysis of the primary endpoint was done at Visit 5 (Week 8/10) in those patients who were on study drug at this visit.
Reported as:
Mean · score on a scale
Change From Baseline in Levodopa-induced Dyskinesia as Measured by UDysRS Score
score on a scalePridopidine TotalPlacebo
Baseline32.0 ± 10.4435.9 ± 6.44
Visit 514.7 ± 5.1326.1 ± 11.02
Change from baseline at Visit 5-17.3 ± 6.03-9.7 ± 9.43

Adverse events

Collected over From screening onwards, through to Week 18 (planned); this included 2 weeks' safety follow-up after treatment completion. The study was discontinued early due to the COVID-19 pandemic. Actual exposure (mean treatment duration) was 38 days in all patients receiving pridopidine and 93 days in all patients receiving placebo.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pridopidine 100 mg BID0/12 (0%)0/12 (0%)10/12 (83.3%)
Pridopidine 150 mg BID0/3 (0%)0/3 (0%)3/3 (100%)
Placebo0/8 (0%)1/8 (12.5%)7/8 (87.5%)
Most frequent serious events
Most frequent serious events
EventPridopidine 100 mg BIDPridopidine 150 mg BIDPlacebo
DiverticulitisInfections and infestations0/120/31/8
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPridopidine 100 mg BIDPridopidine 150 mg BIDPlacebo
Dry eyeEye disorders1/121/30/8
Dry mouthGastrointestinal disorders3/121/30/8
FatigueGeneral disorders3/121/31/8
Oedema peripheralGeneral disorders0/121/30/8
Temperature intoleranceGeneral disorders0/121/30/8
NasopharyngitisInfections and infestations1/121/30/8
FallInjury, poisoning and procedural complications0/121/30/8
Bacterial test positiveInvestigations0/121/30/8
Protein urine presentInvestigations0/121/30/8
Weight decreasedInvestigations0/121/30/8

Baseline characteristics

A total of 8 patients were randomized to pridopidine 150 mg BID. Of these, 5 patients discontinued study drug during titration, i.e. did not reach the full maintenance dose. Therefore, they were analyzed under the 100 mg BID group. The 100 mg BID group included patients who received any dose between 75 mg QD and 100 mg BID.

Age, Continuous
Age, Continuous(years)Pridopidine 100 mg BIDPridopidine 150 mg BIDPlaceboTotal
Mean69.0 ± 7.561.3 ± 12.764.0 ± 9.766.3 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Pridopidine 100 mg BIDPridopidine 150 mg BIDPlaceboTotal
Female71513
Male52310
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pridopidine 100 mg BIDPridopidine 150 mg BIDPlaceboTotal
American Indian or Alaska Native0000
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American0022
White113519
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Pridopidine 100 mg BIDPridopidine 150 mg BIDPlaceboTotal
United States123823
08

Study locations

33 sites
  • Prilenia Investigational Site (Site 117)
    Birmingham, Alabama 35233, United States
  • Prilenia Investigational Site (Site 144)
    Phoenix, Arizona 85004, United States
  • Prilenia Investigational Site (Site 111)
    Phoenix, Arizona 85013, United States
  • Prilenia Investigational Site (Site 115)
    Scottsdale, Arizona 85259, United States
  • Prilenia Investigational Site (Site 106)
    Fountain Valley, California 92708, United States
  • Prilenia Investigational Site (Site 109)
    Irvine, California 92697, United States
  • Prilenia Investigational Site (Site 105)
    Pasadena, California 91105, United States
  • Prilenia Investigational Site (Stie 142)
    Torrance, California 90502, United States
  • Prilenia Investigational Site (Site 136)
    Aurora, Colorado 80045, United States
  • Prilenia Investigational Site (Site 135)
    Englewood, Colorado 80113, United States
  • Prilenia Investigational Site (Site 118)
    Boca Raton, Florida 33431, United States
  • Prilenia Investigational Site (Site 131)
    Maitland, Florida 32751, United States
  • Prilenia Investigational Site (Site 122)
    Sunrise, Florida 33351, United States
  • Prilenia Investigational Site (Site 116)
    Tampa, Florida 33612, United States
  • Prilenia Investigational Site (Site 138)
    Atlanta, Georgia 30329, United States
  • Prilenia Investigational Site (Stie 123)
    Augusta, Georgia 30912, United States
  • Prilenia Investigational Site (Site 107)
    Iowa City, Iowa 52242, United States
  • Prilenia Investigational Site (Site 102)
    Kansas City, Kansas 66160, United States
  • Prilenia Investigational Site (Site 126)
    Omaha, Nebraska 68198, United States
  • Prilenia Investigational Site (Site 141)
    New Brunswick, New Jersey 08901, United States
  • Prilenia Investigational Site (Site 128)
    Amherst, New York 14226, United States
  • Prilenia Investigational Site (Site 147)
    New York, New York 10029, United States
  • Prilenia Investigational Site (Site 101)
    Raleigh, North Carolina 27607, United States
  • Prilenia Investigational Site (Site 127)
    Raleigh, North Carolina 27612, United States
  • Prilenia Investigational Site (Site 149)
    Dayton, Ohio 45459, United States
  • Prilenia Investigational Site (Site 139)
    Tulsa, Oklahoma 74136, United States
  • Prilenia Investigational Site (Site 114)
    Philadelphia, Pennsylvania 19107, United States
  • Prilenia Investigational Site (Site 146)
    Willow Grove, Pennsylvania 19090, United States
  • Prilenia Investigational Site (Site 119)
    Providence, Rhode Island 02903, United States
  • Prilenia Investigational Site (Site 120)
    Houston, Texas 77030, United States
  • Prilenia Investigational Site (Site 121)
    Houston, Texas 77030, United States
  • Prilenia Investigational Site (Site 129)
    San Antonio, Texas 78230, United States
  • Prilenia Investigational Site (Site 103)
    Kirkland, Washington 98034, United States
09

References and documents

Publications

  • McFarthing K, Prakash N, Simuni T. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002. No abstract available. PubMed 31356217 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jul 2020, 14 months.

Results were first posted in Jul 2022, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 22, 2019
StartActual
May 22, 2019
Primary completionActual
Jul 22, 2020
CompletionActual
Jul 22, 2020
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03922711
Lead sponsor
Prilenia
Responsible party
Sponsor
First posted
Apr 22, 2019
Start date
May 22, 2019
Primary completion
Jul 22, 2020
Completion
Jul 22, 2020
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Yael Cohen
study director · Prilenia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pridopidine

Start the discussion